[Importance of the "adequate blood phosphorus" concept as a risk factor for hyperphosphatemia]
- PMID: 12778863
[Importance of the "adequate blood phosphorus" concept as a risk factor for hyperphosphatemia]
Abstract
Hyperphosphatemia is an important risk factor of secondary hyperparathyroidism and extraosseous calcifications in chronic renal failure patients. In this study our hypothesis is that physicians misconception of adequate phosphatemia is a risk factor for hyperphosphatemia. In 1999 GEMOR sent a renal osteodystrophy inquiry to different hemodialysis centers in Argentina. It included 80 dialysis centers in 17 Argentinian provinces. The enquire had 33 questions about renal osteodystrophy. Here we report the section related to phosphorous metabolism. We obtained responses from 80 dialysis centers (4,512 dialysis patients), which represents about 24% of Argentinian dialysis centers. Physicians considered phosphorous levels between 4.5 to 5.5 mg/dl in 83.5% of centers as adequate, and between 5.5 to 6.5 mg/dl in 10.1%. Five out of 77 centers reported that they had no patients with hyperphosphatemia. The percentage of hemodialysis patients that had more than 6 mg/dl in each center was 28.8 +/- 15.9%. Those centers that aimed for phosphatemia between 5.5 and 6.5 mg/dl, had a higher percentage of patients with phosphatemia above 6 mg/dl than those aiming for between 4.5 and 5.5 mg/dl (42.8 +/- 16.7 vs 27.1 +/- 15.2% respectively, p = 0.007), and had higher mean of phosphatemia (6.4 +/- 0.7 vs 5.3 +/- 0.7 mg/dl respectively, p = 0.0001), than the last group. In conclusion, a higher mean phosphate level was obtained in hemodialysis centers where physicians considered higher pre-dialysis target levels. Some centers had no patients with hyperphosphatemia (neglect or good control?).
Similar articles
-
Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.Am J Kidney Dis. 2000 Jun;35(6):1226-37. doi: 10.1016/s0272-6386(00)70064-3. Am J Kidney Dis. 2000. PMID: 10845841 Review.
-
The influences of method of calcium correction and the timing of blood collection on application of the K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Japan.Ther Apher Dial. 2006 Jun;10(3):257-61. doi: 10.1111/j.1744-9987.2006.00333.x. Ther Apher Dial. 2006. PMID: 16817790
-
Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.Expert Opin Pharmacother. 2008 Mar;9(4):601-10. doi: 10.1517/14656566.9.4.601. Expert Opin Pharmacother. 2008. PMID: 18312161 Review.
-
Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).Saudi J Kidney Dis Transpl. 2010 Jan;21(1):93-101. Saudi J Kidney Dis Transpl. 2010. PMID: 20061700
-
Understanding and managing hyperphosphatemia in patients with chronic renal disease.Clin Nephrol. 1999 Nov;52(5):267-77. Clin Nephrol. 1999. PMID: 10584989 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources